Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-12-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于公司2025年度日常关联交易额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected daily related-party transaction limits for the year 2025 by 科兴生物制药股份有限公司. It details the nature, amounts, counterparties, and approval procedures of these related-party transactions. The document includes information about board and audit committee approvals, transaction pricing policies, and the impact on the company and shareholders. It is a regulatory announcement about related-party transactions and does not contain financial statements, audit opinions, or detailed financial results. It is not a full annual or interim report, nor is it a call transcript or management report. It is also not a voting result or capital change announcement. The document is a regulatory filing informing the market about related-party transactions and their expected limits, consistent with regulatory disclosure requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (over 11,000 characters) and detailed content confirm it is not a brief report publication announcement or a certification letter.
2024-12-27 Chinese
关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属结果暨股份上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of the registration and listing of shares related to the company's 2022 restricted stock incentive plan's second vesting period and reserved grant's first vesting period. It details the number of shares vested, the decision-making process, the stock listing date, and the impact on share capital and earnings per share. The document includes references to board and supervisory meetings approving the plan and the issuance of shares, as well as a verification report from an accounting firm. It is a formal announcement about the stock incentive plan's share registration and listing, not a full financial report or detailed management discussion. The document length is about 6,271 characters, which is sufficient for a detailed announcement but does not contain comprehensive financial statements or management analysis. It is not an annual or interim report, nor an earnings release or management report. It is not a proxy statement or voting result announcement. It is a capital change announcement related to share issuance under a stock incentive plan. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2024-11-01 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions from the 2024 third extraordinary shareholders' meeting of 科兴生物制药股份有限公司. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis but reports on the voting outcomes of specific proposals, such as the change of accounting firm. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, not a full report or presentation.
2024-10-28 Chinese
关于召开2024年第三季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling of a 2024 third quarter earnings explanation meeting (业绩说明会) by 科兴生物制药股份有限公司. It mentions the date, time, location, and format of the meeting, as well as instructions for investors to submit questions. It references the prior release of the 2024 Q3 report but does not contain any financial data or detailed results itself. The document is short (1381 characters) and serves as a notice for an upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or related notice. However, since it is announcing the meeting and inviting participation rather than providing the presentation content, it is more accurately classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the event and does not contain the actual presentation or financial data. The document is not a full report, call transcript, or earnings release. Hence, the best classification is Regulatory Filings (RNS) with high confidence.
2024-10-28 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2024年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2024 third extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on legal compliance and validation of the meeting process and voting outcomes. It is not an announcement of voting results per se but a legal opinion on the meeting's legality. Given the content and nature, this fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and announcement of shareholder meeting voting results and procedures.
2024-10-28 Chinese
2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '科兴生物制药股份有限公司 2024 年第三季度报告' which translates to 'Sinovac Biopharmaceutical Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data for the third quarter of 2024, including balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance and business operations. The report explicitly states it is a quarterly report (第三季度报告) and includes unaudited financial statements for the period ending September 30, 2024. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.